-
14 over 100 million proprietary Chinese medicine plasters exposed!
Time of Update: 2021-06-22
According to data from Meinenet, the market share of terminal pain relief plasters in physical pharmacies in Chinese cities has maintained steady growth in recent years, with sales exceeding 600 million yuan in 2020 .
-
Is prescription drug retail a good business?
Time of Update: 2021-06-22
Therefore, although small chain and individual pharmacies still have a certain market share, the prescription drug retail market is ultimately concentrated in the hands of a few large pharmacies and PBMs .
-
Trilaciclib introduced by Simcere has been approved for clinical use
Time of Update: 2021-06-22
The latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China shows that Trilaciclib for injection, jointly declared by Simcere and G1 Therapeutics, has obtained an implied license for a clinical trial to prescribe the treatment of triple-negative breast cancer .
-
Zhang Jinjun, deputy general manager of Qianke Biology, resigns
Time of Update: 2021-06-22
According to the announcement, the company’s board of directors recently received a written resignation report from the company’s deputy general manager Zhang Jinjun .
Zhang Jinjun applied to resign from the position of deputy general manager of the company due to personal reasons .
-
Resignation of the chairman, some directors and general manager of Tianyao Pharmaceutical
Time of Update: 2021-06-22
Zhang Jie applied to resign from the company’s eighth board of directors and directors, Mr.
Yang Fuzhen applied to resign from the company’s eighth board of directors and general manager Position .
-
Jingfeng Pharmaceutical Letrozole Tablets Obtained Drug Registration Approval
Time of Update: 2021-06-22
It is reported that letrozole is a selective, non-steroidal aromatase inhibitor, which has no negative effects on the secretion of glucocorticoids and mineralocorticoids and thyroid function .
It is also suitable for the treatment of postmenopausal, estrogen receptor-positive, progesterone-receptor-positive, or advanced breast cancer patients whose receptor status is unknown.
-
BeiGene Baizean's new indications for listing application are accepted in China
Time of Update: 2021-06-22
BeiGene announced today that the NMPA Drug Evaluation Center has accepted its anti-PD-1 antibody drug Bezan for the treatment of previously treated, locally advanced unresectable or metastatic highly microsatellite unstable (MSI-H) or wrong Application for new indications for patients with solid tumors with defective repair (dMMR) .
-
The United States approves the first Alzheimer's disease drug in the past 20 years at an annual cost of 56,000 US dollars
Time of Update: 2021-06-22
S. Food and Drug Administration (FDA) issued a statement on its official website stating that it approved the Aduhelm (aducanumab) developed by the pharmaceutical company Biogen to treat patients with Alzheimer’s disease.
It is the first new treatment approved for Alzheimer's disease since 2003 .
-
Tetrabenazine tablets are approved soon for the treatment of Huntington's disease
Time of Update: 2021-06-22
1 new drug tetrabenazine tablets (the relevant acceptance number is JXHS2000123/124), and it is expected to be officially approved soon and become the second domestic approval.
-
Global AI+ R&D competition!
Time of Update: 2021-06-22
In September 2020, Jingtai Technology, an AI drug research and development company driven by digitization and intelligence, completed a $319 million Series C financing, setting a record for the highest financing amount in the global AI drug research and development field at that time .
-
The adjustment of the medical insurance catalogue starts! Plans to add 4 types of drugs to be approved before June 30, new drugs can be declared
Time of Update: 2021-06-22
For the first time, it is proposed to focus on drugs that have been in the catalog before January 1, 2016, and that there is no purchase record on the national drug procurement platform from January 1, 2016 to June 30, 2021 .
-
Healthyuan Omeprazole Sodium for Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-06-22
On June 15th, Joincare announced that Livzon Pharmaceutical Factory, a wholly-owned subsidiary, received the "Drug Supplement Application Approval Notice" approved and issued by the National Medical Products Administration.
The omeprazole sodium for injection produced by Livzon Pharmaceutical Factory passed Consistency evaluation of the quality and efficacy of generic drugs .
-
Mistletoe has a bright prospect for medicinal use, and the future market is bullish year by year!
Time of Update: 2021-06-22
After entering the 21st century, with the continuous deepening of scientific research, the use of mistletoe has been expanded to varying degrees, the market share has increased day by day, and the demand has also shown an upward trend year by year .
-
Announcement of the results of the planned selection of Shanghai centralized drug procurement (SH-DL2021-1)
Time of Update: 2021-06-22
Publicity time: June 8, 2021 to June 10, 2021According to the content of the announcement, the results of the proposed selection include 9 specifications including Olanzapine and Gefitinib .
Attachment: Shanghai Centralized Pharmaceutical Procurement (SH-DL2021-1) Proposed Selection Results
-
ASCO annual meeting grand opening!
Time of Update: 2021-06-22
According to reports, the RATIONALE 302 study is a randomized, open, multi-center, global phase 3 clinical trial designed to evaluate tislelizumab versus chemotherapy selected by investigators as the second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma Effectiveness and safety .
-
The Central Procurement of the Chinese Patent Medicine Alliance will be launched: Is the price cut coming?
Time of Update: 2021-06-22
In 2020, the inter-provincial alliance of 11 provinces and regions will start the centralized procurement of drugs, which is voluntary for 11 provinces (districts, corps) including Shaanxi, Hunan, Hainan, Shanxi, Guangxi, Guizhou, Gansu, Ningxia, Qinghai, Xinjiang, and Xinjiang Production and Construction Corps.
-
The third indication of Cinda PD-1 was approved as the first-line treatment for squamous NSCLC
Time of Update: 2021-06-22
ORIENT-12 is the world's first PD-1 monoclonal antibody combined with gemcitabine and platinum (GP regimen) for advanced sqNSCLC A randomized, double-blind, phase III controlled clinical study of first-line treatment .
-
Li Haibing, deputy general manager of Beilu Pharmaceutical, resigns
Time of Update: 2021-06-22
Li Haibing and applied for resignation from his position as deputy general manager .
Li Haibing's resignation report will take effect from the date of delivery to the company's board of directors, and his resignation will not affect the company's normal operations .
-
Viewing the Investment Choice of Pharmaceutical Enterprises from Yunnan Baiyao
Time of Update: 2021-06-22
In 2020, the income from changes in the fair value of Fosun Pharma's financial assets was 559 million yuan, ranking fourth among A-share listed pharmaceutical companies; investment income was 2.
-
The national "medical insurance bill" releases multiple signals
Time of Update: 2021-06-22
Whether it is the total income data or total expenditure data of the medical insurance fund, or data such as the number of doctors, the price of medical insurance drugs, and the situation of medical treatment in different places, it is the livelihood information of the public's concern .
